← 產業報告目錄
Erectile Dysfunction Drugs Market by Drug (Avanafil (Stendra), Muse Suppository (Alprostadil), Sildenafil (Viagra)), Mode of Administration (Injections, Oral, Topical), Distribution Channel, Region And Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-22頁數 180報告編號 INSIGHTACE-98aaa75623
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
In 2023, the Erectile Dysfunction Drugs Market by Drug (Avanafil (Stendra) worldwide was assessed at USD 2.58 billion. Analysts project it will accelerate to USD 4.60 billion by 2031, at a CAGR of 7.7% spanning 2024 to 2031.
Erectile Dysfunction Drugs by Drug (Avanafil (Stendra) encompasses the condition where an individual is unable to gain or maintain an erection for a sufficient duration to engage in sexual activity. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
The market's upward path is driven by surging healthcare spending, technological evolution, and the surging focus on personalized and precision-based approaches in healthcare.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Erectile Dysfunction Drugs Market Snapshot
Chapter 4. Global Erectile Dysfunction Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Drug Estimates & Trend Analysis
5.1. by Drug & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug:
5.2.1. Avanafil (Stendra)
5.2.2. Muse Suppository (Alprostadil)
5.2.3. Sildenafil (Viagra)
5.2.4. Tadalafil (Cialis)
5.2.5. Vardenafil (Levitra, Staxyn)
Chapter 6. Market Segmentation 2: by Mode of Administration Estimates & Trend Analysis
6.1. by Mode of Administration & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Mode of Administration:
6.2.1. Injections
6.2.2. Oral
6.2.3. Topical
Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis
7.1. by Distribution Channel & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Distribution Channel:
7.2.1. Hospital Pharmacies
7.2.2. Online Pharmacies
7.2.3. Retail Pharmacies
Chapter 8. Erectile Dysfunction Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.1.2. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.1.3. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.1.4. North America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.2.2. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.2.3. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.2.4. Europe Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.3.2. Asia Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.3.3. Asia-Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.3.4. Asia Pacific Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.4.2. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.4.3. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.4.4. Latin America Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2019-2031
8.5.2. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Mode of Administration, 2019-2031
8.5.3. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2019-2031
8.5.4. Middle East & Africa Erectile Dysfunction Drugs Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Adamed Sp. z o.o.
9.2.2. Bayer AG
9.2.3. Cipla Limited
9.2.4. Dr. Reddys Laboratories Ltd.
9.2.5. Eli Lilly and Company
9.2.6. Endo International PLC
9.2.7. Futura Medical PLC
9.2.8. GlaxoSmithKline PLC
9.2.9. Johnson & Johnson Services Inc.
9.2.10. Novartis International AG
9.2.11. Pfizer Inc.
9.2.12. S.K. Chemicals Co. Ltd.
9.2.13. Sanofi S.A.
9.2.14. Sun Pharmaceutical Industries Ltd.
9.2.15. Teva Pharmaceutical Industries Ltd.
9.2.16. Vivus, Inc.
9.2.17. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們